Beam Therapeutics (BEAM)’ treatment of alpha-1 antitrypsin deficiency was granted FDA orphan designation status, according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics announces FDA grants RMAT designation to BEAM-302
- Beam Therapeutics: Promising Gene Editing Advancements and Strategic Execution Reinforce Buy Rating
- Beam Therapeutics: Promising Pipeline and Financial Stability Justify Buy Rating
- Beam Therapeutics: Promising Advancements in Base Editing and Strong Financial Position Support Buy Rating
- Beam Therapeutics price target lowered to $55 from $78 at Guggenheim